These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22225546)

  • 1. Patient preferences for psoriasis treatments: impact of treatment experience.
    Schaarschmidt ML; Umar N; Schmieder A; Terris DD; Goebeler M; Goerdt S; Peitsch WK
    J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):187-98. PubMed ID: 22225546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes.
    Schaarschmidt ML; Schmieder A; Umar N; Terris D; Goebeler M; Goerdt S; Peitsch WK
    Arch Dermatol; 2011 Nov; 147(11):1285-94. PubMed ID: 22106115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comorbidities significantly impact patients' preferences for psoriasis treatments.
    Schmieder A; Schaarschmidt ML; Umar N; Terris DD; Goebeler M; Goerdt S; Peitsch WK
    J Am Acad Dermatol; 2012 Sep; 67(3):363-72. PubMed ID: 22015150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.
    Kromer C; Schaarschmidt ML; Schmieder A; Herr R; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(6):e0129120. PubMed ID: 26058083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient Preferences for Biologicals in Psoriasis: Top Priority of Safety for Cardiovascular Patients.
    Schaarschmidt ML; Kromer C; Herr R; Schmieder A; Sonntag D; Goerdt S; Peitsch WK
    PLoS One; 2015; 10(12):e0144335. PubMed ID: 26633680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment preferences for biologicals in psoriasis: experienced patients appreciate sustainability.
    Kromer C; Peitsch WK; Herr R; Schmieder A; Sonntag D; Schaarschmidt ML
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):189-200. PubMed ID: 28214326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.
    Florek AG; Wang CJ; Armstrong AW
    Arch Dermatol Res; 2018 May; 310(4):271-319. PubMed ID: 29442137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Satisfaction with treatment among patients with psoriasis: a web-based survey study.
    van Cranenburgh OD; de Korte J; Sprangers MA; de Rie MA; Smets EM
    Br J Dermatol; 2013 Aug; 169(2):398-405. PubMed ID: 23565643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of psoriasis: the impact of private versus public insurance.
    Buzney CD; Peterman C; Saraiya A; Au SC; Dumont N; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Feb; 14(2):119-25. PubMed ID: 25689806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
    Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
    J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacalcitol in the treatment of psoriasis vulgaris: the Spanish experience.
    Lecha M; Mirada A; López S; Artés M;
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):414-7. PubMed ID: 15987284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions.
    Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA
    J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient preferences for topical psoriasis treatments: a discrete choice experiment.
    Hoelker S; Ninosu N; Buettner S; Peitsch WK; Schaarschmidt ML
    J Dermatolog Treat; 2022 Aug; 33(5):2595-2604. PubMed ID: 35373695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare).
    Schaarschmidt ML; Herr R; Gutknecht M; Wroblewska K; Gerdes S; Sticherling M; Augustin M; Peitsch WK
    Acta Derm Venereol; 2018 Feb; 98(2):200-205. PubMed ID: 29110022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of psoriasis vulgaris treatments: analysis of treatment with topical corticosteroid and/or vitamin D3 analog, oral cyclosporin, etretinate and phototherapy over a 35-year period, 1975-2010.
    Akasaka E; Mabuchi T; Manabe Y; Yahagi E; Yamada-Hiruma A; Yamaoka H; Kojima T; Kato M; Ikoma N; Ozawa A; Haruki Y
    J Dermatol; 2013 Apr; 40(4):238-43. PubMed ID: 23330814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient benefit index (PBI) in the treatment of psoriasis--results of the National Care Study "PsoHealth".
    Radtke MA; Schäfer I; Blome C; Augustin M
    Eur J Dermatol; 2013 Apr; 23(2):212-7. PubMed ID: 23587940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis.
    Seston EM; Ashcroft DM; Griffiths CE
    Arch Dermatol; 2007 Sep; 143(9):1175-9. PubMed ID: 17875880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey.
    Nijsten T; Margolis DJ; Feldman SR; Rolstad T; Stern RS
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):434-44. PubMed ID: 15761421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan.
    Feldman SR; Evans C; Russell MW
    J Dermatolog Treat; 2005 Feb; 16(1):37-42. PubMed ID: 15897166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.